By Fineline Cube 
Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).
Financial Performance Summary
| Metric | Q2 2026 | YOY Change (CER) |
|---|---|---|
| Net Sales | EUR 11.6B (USD 13.4B) | +17.8% |
| Pharma Launches Sales | EUR 1.3B (USD 1.5B) | +48.3% |
| Dupixent Sales | EUR 5.2B (USD 6.0B) | +37.6% |
| Vaccines Sales | EUR 1.1B (USD 1.3B) | -4.7% |
Business Segment Highlights
- Pharma Launches: Increased by 48.3% to EUR 1.3 billion, driven mostly by Ayvakit, ALTUVIIIO, and Sarclisa
- Dupixent (dupilumab): Sales grew 37.6% to EUR 5.2 billion, exceeding EUR 5 billion in a single quarter for the first time
- Vaccines: Sales decreased by 4.7% to EUR 1.1 billion, impacted by a high basis of comparison in influenza vaccines
Strategic Guidance Update
Based on strong performance in the first half and anticipating normalization of growth in the second half, Sanofi has upgraded its 2026 guidance:
- Sales Growth: Now expecting around 10% at CER (upgraded from previous guidance)
- Business EPS: Expected to grow slightly faster than sales
Market Context & Competitive Positioning
Sanofi’s exceptional Q2 performance demonstrates the company’s successful execution of its strategic transformation, with Dupixent continuing to exceed expectations as a blockbuster immunology asset. The 48.3% growth in pharma launches highlights the successful commercialization of recent product introductions across multiple therapeutic areas.
The slight decline in vaccines sales reflects challenging year-over-year comparisons rather than underlying business weakness, as the influenza vaccine market experienced exceptional demand in the prior year period.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, growth expectations, and business outlook. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, and other risk factors.-Fineline Info & Tech